Dapagliflozin cardiovascular effects on end-stage kidney disease (DARE-ESKD-2) trial: rationale and design.

Joaquim Barreto OliveiraMarilia MartinsMauro PascoaSheila T K MedorimaIsabella BonilhaDaniel Campos JesusCinthia E M CarbonaraKelcia R S QuadrosBarbara AssatoAlessandra M Campos-StafficoGil Guerra JúniorWilson NadruzRodrigo B de OliveiraAndrei C Sposito

Published in: Research square (2023)

The DARE-ESKD-2 trial will provide unprecedented data on the cardiovascular safety and efficacy of SGLT2i in ESKD individuals on dialysis. This study will pave the grounds for improving clinical outcomes of dialysis recipients.

Keyphrases

chronic kidney disease
phase iii
study protocol
end stage renal disease
phase ii
clinical trial
peritoneal dialysis
big data
open label
deep learning
kidney transplantation
artificial intelligence